capecitabine brands

22 registered brands containing capecitabine in Kenya.

Capecitabine 2D chemical structure

2D structure

Capecitabine

PubChem CID 60953

Molecular formula: C15H22FN3O6

Capecitabine is metabolized to 5-fluorouracil in vivo by carboxylesterases, cytidine deaminase, and thymidine phosphorylase/uridine phosphorylase sequentially. 5-fluorouracil is further metabolized through a series of enzymatic reactions into 3 main active metabolites: 5-fluorouridine triphosphate (5-FUTP), 5-fluoro-2’-deoxyuridine monophosphate (5-FdUMP), and 5-fluorodeoxyuridine triphosphate (5-FdUTP).. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate (CH<sub>2</sub>THF), bind to thymidylate synthase (TS) to form a covalently bound ternary complex. TS is an enzyme that catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Under normal physiological conditions, dUMP binds to TS first before CH<sub>2</sub>THF, followed by a 1,4 or Michael addition from the pyrimidine C (6)atom to the Cys146 nucleophile. If correctly positioned, dUMP, CH<sub>2</sub>THF, and TS would form a ternary complex to facilitate the donation of the methyl group from CH<sub>2</sub>THF to dUMP. However, the substitution of dUMP with FdUMP results in a new time-dependent TS–FdUMP–CH2THF complex. Since the fluorine group prevents dissociation of FdUMP from the pyrimidine ring, the whole complex is rendered irreversibly deactivated, terming this reaction "suicide inhibition". TS inhibition prevents the conversion of dUMP to dTMP, depleting the pool of dTMP that could be phosphorylated into dTTP to be incorporated as DNA nucleotides. This disrupts the nucleotides balance, particularly the the ATP/dTTP ratio, thus impairing DNA synthesis and repair and causing apoptosis. 5-FdUMP can also be phosphorylated into 5-FdUTP, further increasing the pool of dUTP base to potentially overwhelm the activity of dUTPase. Coupled with the decrease in dTTP, 5-FdUMP, and 5-FdUTP increase the probability of mistakenly incorporating a uracil base into DNA strands in place of thymine. Although this mistake can often be resolved by the nucleotide excision repair enzyme uracil-DNA-glycosylase (UDG), the high (F)dUTP/dTTP ratio would result in re-incorporation of uracil into DNA, leading to a futile cycle of misincorporation, excision, and repair. Repeated base excision repair can result in abasic sites, which can lead to DNA mutagenesis and thus protein miscoding, replication forks collapse, and DNA fragmentation through single or double strand breaks However, several reports have found that the incorporation of uracil in genomic DNA does not significantly affect the cytotoxicity of 5-FU, suggesting that the cytotoxic effect of 5-FU is dominated by the perturbation of RNA through 5-FUTP. Similar to 5-dFUTP, 5-FUTP can be mistakenly incorporated into RNA in place of regular UTP and disrupt regular RNA biology through various mechanisms. 5-FUTP can be incorporated into the spliceosomal U2 snRNA at pseudouridylated sites to prevent further pseudouridylation and thus pre-mrNA splicing. 5-FUTP can also change the structure of U4 and U6 snRNA and reduce the turnover rate of U1 snrNA once incorporated. For tRNA, 5-FUTP can affect tRNA's post-transcriptional RNA modifications activity, particularly by inhbiting pseudouridine synthase through formation of covalent complex. Recently, the effect of 5-FUTP on miRNAs and lncRNA was also observed through profound changes in expression, although the precise mechanism is still unknown. Although the main mechanism of 5-FU cytotoxicity was thought to be attributed to DNA damages, recent reports have shown that the majority of 5-FU pharmacological action is mediated through RNA, since 5-FU is accumulated ~3000- to 15 000-fold more in RNA compared to that of DNA. Capecitabine is a prodrug and has little pharmacologic activity until it is converted to fluorouracil, an antimetabolite. Because capecitabine is converted to fluorouracil by enzymes that are expressed at higher concentrations in many tumors than in adjac

Source: PubChem (NCBI) · compound 60953

Product Manufacturer Status Country
BDOCIN 150
CAPECITABINE USP 150MG
Ripple Pharmaceuticals Registered Kenya
BDOCIN 500 BDR
500MG
Ripple Pharmaceuticals Registered Kenya
CAPECIKEN 500
CAPECITABINE TABLETS USP 500MG
Krishna Chemists Registered Kenya
CAPECITABINE SANDOZ 150MG
150MG
Laborex Kenya Registered Kenya
CAPECITABINE SANDOZ 500MG
500MG
Laborex Kenya Registered Kenya
CAPECITABINE TABLETS USP 500MG
500MG
Psm Pharmaceuticals Registered Kenya
CAPECITABINE-DRLA
500 MG
Eah Care Registered Kenya
CAPECITACARE 500
CAPECITABINE USP 500 MG
Zuvan Limited Registered Kenya
CAPEMAX-150MG
CAPECITABINE 150MG
Accord Healthcare Registered Kenya
CAPEMAX-150mg
Tablet
Intas Pharmaceuticals Ltd Retained Kenya
CAPEMAX-500MG
CAPECITABINE 500MG
Accord Healthcare Registered Kenya
CAPEMS 500
500 MG
Msn Laboratories Registered Kenya
CAPETERO 150
EACH FILM COATED TABLET CONTAINS 150 MG OF CAPECITABINE USP.
Unisel Registered Kenya
CAPETERO 500
EACH FILM COATED TABLET CONTAINS 500 MG OF CAPECITABINE USP.
Unisel Registered Kenya
CAPETERO 500
Film-Coated Tablet
Hetero Labs Ltd Retained Kenya
CAXETA 500 TABLETS
CAPECITABINE
Sun Pharma Registered Kenya
GLOCAPX 500
500MG
Evka Consultz Registered Kenya
NAPROCAP
500 MG
Ripple Pharmaceuticals Registered Kenya
PACSITA 150
150 MG PER UNIT
Simba Pharmaceuticals Registered Kenya
PACSITA 500
500 MG PER UNIT
Simba Pharmaceuticals Registered Kenya
XELODA 150
CAPECITABINE 150MG
Roche - Kenya
XELODA 500
CAPECITABINE 500MG
Laborex Kenya Registered Kenya